Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)

BACKGROUND: SWOG S0421 was a large randomized trial comparing docetaxel/prednisone plus placebo (DPP) to docetaxel/prednisone plus atrasentan over 12 cycles for patients with metastatic castration-resistant prostate cancer (mCRPC). The current report presents the PRO results for this trial, an impor...

Descripción completa

Detalles Bibliográficos
Autores principales: Unger, Joseph M., Griffin, Katherine, Donaldson, Gary W., Baranowski, Karen M., Good, Margorie J., Reburiano, Eunicia, Hussain, Maha, Monk, Paul J., Van Veldhuizen, Peter J., Carducci, Michael A., Higano, Celestia S., Lara, Primo N., Tangen, Catherine M., Quinn, David I., Wade, James L., III, Vogelzang, Nicholas J., Thompson, Ian M., Jr, Moinpour, Carol M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5997724/
https://www.ncbi.nlm.nih.gov/pubmed/29951640
http://dx.doi.org/10.1186/s41687-018-0054-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5997724/
https://www.ncbi.nlm.nih.gov/pubmed/29951640
http://dx.doi.org/10.1186/s41687-018-0054-5

Ejemplares similares